GL1X · GenesisL1 explorer

MolNFT v1 · #187600 · protein

P107 pocket domain complexed with mutated HDAC1-3X peptide

7SMF · Retinoblastoma-like protein 1: “P107 pocket domain complexed with mutated HDAC1-3X peptide”. X-ray diffraction, 1 ligand (SO4), 10 pockets (best druggability 0.74). MolNFT v1 #187600 on GenesisL1: 3D structure, binding sites and…

PDB
7SMF
Type
protein
Length
704 residues
Chains
4
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Retinoblastoma-like protein 1; Histone deacetylase 1
EC
3.5.1.98, 3.5.1.-
UniProt
P28749
Ligands
SO4
Pockets
10 · best druggability 0.74

Structure

x-ray diffraction · 2 distinct chains · 57% helix, 1% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
A, CRetinoblastoma-like protein 1protein34259% helix, 1% strandP28749
B, DHistone deacetylase 1 (EC 3.5.1.98, 3.5.1.-)protein100% helix, 0% strand—

Ligands and binding sites

  • SO4 · Sulfate ion · ion · 4 copies · chains A, C

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

10 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
18050.740.7986empty
22000.520.7824empty
3970.490.8219empty
41160.420.7618empty
5990.380.7518empty

Interfaces

3 interfaces between chains.

  • A–C · 1080 Ų buried · 14 hydrogen bonds · protein-protein
  • C–D · 687 Ų buried · 8 hydrogen bonds · protein-protein
  • A–B · 652 Ų buried · 6 hydrogen bonds · protein-protein

Compared structures

  • 7SMF · p107 pocket domain complexed with mutated HDAC1-3X peptide · the same entry in another collection · chain A against A, TM-score 1.00
  • P28749 · AlphaFold monomer V2.0 prediction for retinoblastoma-like protein 1 (P28749) · a predicted model of the same protein · chain A against A, TM-score 0.99

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.